Zusammenfassung
Gegen den Tumornekrosefaktor (TNF) α gerichtete Therapeutika werden zunehmend erfolgreich in der Therapie der Psoriasis vulgaris und Psoriasisarthritis eingesetzt. Wir berichten über einen Patienten mit TNF-Rezeptor-1-assoziiertem periodischem Syndrom (TRAPS), bei dem eine Therapie mit dem TNF-α-Antagonisten Etanercept initiiert wurde. Einen Monat später stellte sich der Patient mit der Erstmanifestation einer Psoriasis vulgaris vom Plaquetyp vor. Dieses als paradox erscheinende Phänomen wurde bereits in Einzelfällen als Folge der Anti-TNF-α-Therapie anderer inflammatorischer Erkrankungen beobachtet. Die Ursache der TNF-α-Antagonisten-induzierten Psoriasis ist bisher unklar.
Abstract
Drugs antagonizing tumor necrosis factor (TNF) α have been increasingly and successfully used in the treatment of psoriasis vulgaris and psoriatic arthritis. We report a patient with TNF receptor 1-associated periodic syndrome (TRAPS) who received TNF-α antagonist etanercept. A month later, the patient developed for the first time generalized psoriasis vulgaris. This paradoxical phenomenon has been reported sporadically in patients receiving TNF-α antagonists for other inflammatory diseases. The cause of psoriasis induced by TNF-α antagonists is still obscure.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Bhatia A, Kast RE (2007) Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease. J Rheumatol 34: 447–449
Church LD, Churchman SM, Hawkins PN, McDermott MF (2006) Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 27: 494–508
Dutz JP (2007) Tumor necrosis factor-a inhibition and palmoplantar pustulosis: Janus-faced therapy? J Rheumatol 34: 247–249
Gannes G, Ghoreishi M, Pope J et al. (2007) Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 143: 223–231
Hull KM, Drewe E, Aksentijevich I et al. (2002) The TNF receptor-associated periodic syndrome (TRAPS). Emerging concepts of an autoinflammatory disorder. Medicine 81: 349–368
Kary S, Worm M, Audring H et al. (2006) New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Ann Rheum Dis 65: 405–407
Mease P (2004) Psoriasis arthritis. TNF α therapy in psoriatic arthritis and psoriasis. How and why does it work? Ann Rheum Dis 63: 755–758
Nowlan ML, Drewe E, Bulsara H et al. (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology 45: 31–37
Pirard D, Arco D, Debrouckere V, Heenen M (2006) Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 213: 182–186
Reimold AM (2003) New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 325: 75–92
Sfikakis PP, Iliopoulos A, Elezoglou A et al. (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheumatism 52: 2513–2518
Sfikakis PP, Kollias G (2003) Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 15: 380–386
Touitou I, Lesage S, McDermott M et al. (2004) Infevers an evolving mutation database for autoinflammatory syndromes. Hum Mutat 24: 194
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boms, S., Sehr, T., Jappe, U. et al. Erstmanifestation einer Psoriasis vulgaris bei Tumornekrosefaktor-Rezeptor-1-assoziiertem periodischem Syndrom unter Therapie mit Etanercept. Hautarzt 59, 653–655 (2008). https://doi.org/10.1007/s00105-007-1451-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-007-1451-5